期刊文献+

5-Aza-CdR增强TRAIL对胃癌细胞的抗瘤活性与caspase-8表达的关系 被引量:4

Enhanced TRAIL antitumor activity on human gastric cancer cells induced by 5-Aza-CdR is involved in up-regulation of caspase-8
下载PDF
导出
摘要 目的 探讨 5 Aza CdR对凋亡诱导分子TRAIL抗胃癌细胞活性的影响。方法 采用MTT方法检测TRAIL蛋白的抗癌活性 ;采用RT PCR方法检测caspase 8mRNA的表达。结果 TRAIL 2 0 0ng/ml作用 72h对SGc 790 1、Kato 3和AGS胃癌细胞的生长抑制率分别为 9 83 %、11 94%和 4 0 4% ;经 5 Aza CdR处理后 ,对 3株胃癌细胞的抑制率分别提高到3 8 98%、5 2 42 %和 3 0 72 % ;用 5 Aza CdR处理后 3株胃癌细胞caspase 8mRNA表达明显增加。结论  5 Aza CdR能增强胃癌细胞对TRAIL的敏感性 ,其机制可能与caspase 8的表达上调有关。 Objective To study the effects of demethylation agent 5-Aza-2′-deoxycytidine (5-Aza-CdR) on the antitumor activity of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) against gastric carcinoma. Methods Expression of caspase-8 mRNA was examined by RT-PCR. Antitumor activity of TRAIL protein was measured by MTT method. Results The inhibition rates of treatment with 200 ng/ml TRAIL for 72 h on gastric cell lines SGc 7901, Kato 3, and AGS were 9.83%, 11.94%, and 4.04%. After treatment with 5-Aza-CdR, the inhibition rates of 200 ng/ml TRAIL on gastric cell lines increased to 38.98%, 52.42%, and 30.72%. Before exposure to 5-Aza-CdR, expression of caspase-8 mRNA was low and an increased expression of the caspase-8 was found in the three gastric cancer cells after treatment with 5-Aza-CdR. Conclusion Treatment with 5-Aza-CdR can increase TRAIL antitumor activity on human gastric cancer and its mechanisms might be involved in the up-regulation of caspase-8 gene.
出处 《第三军医大学学报》 CAS CSCD 北大核心 2005年第2期95-97,共3页 Journal of Third Military Medical University
基金 全军医学科研"十五"计划面上项目 ( 0 1MA172 )~~
关键词 胃癌 5-AZA-CDR TRAIL CASPASE-8 gastric carcinoma 5-Aza-2'-deoxycytidine tumor necrosis factor-related apoptosis-inducing ligand caspase-8
  • 相关文献

参考文献13

  • 1李小安,房殿春,杨仕明,罗元辉.TRAIL蛋白的表达、纯化和抗肿瘤活性[J].第三军医大学学报,2001,23(9):1058-1060. 被引量:14
  • 2Wiley S R, Schooley K, Smolak P J, et al. Identification and characterization of a new member of the TNF family that induces apoptosis[J]. Immunity, 1995, 3(6): 673-682.
  • 3Pitti R M, Marsters S A, Ruppert S, et al. Ashkenazia. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family[J]. J Biol Chem, 1996, 271(22): 12687-12690.
  • 4Ashkenazi A, Pai R C, Fang S, et al. Safety and antitumor activity of recombinant soluble APO2 ligand[J]. J Clin Invest, 1999, 104(2): 155-162.
  • 5Harada K, Toyooka S, Shivapurkar N, et al. Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines[J]. Cancer Res, 2002, 62(20): 5897-5901.
  • 6Zuzak T J, Steinhoff D F, Sutton L N, et al. Loss of caspase-8 mRNA expression is common in childhood primitive neuroectodermal brain tumour/medulloblastoma[J]. Eur J Cancer, 2002, 38(1): 83-91.
  • 7Hopkins-Donaldson S, Ziegler A, Kurtz S, et al. Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation[J]. Cell Death Differ, 2003, 10(3): 356-364.
  • 8Fulda S, Kufer M U, Meyer E, et al. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer[J]. Oncogene, 2001, 20(41): 5865-5877.
  • 9Takita J, Yang H W, Chen Y Y, et al. Allelic imbalance on chromosome 2q and alterations of the caspase 8 gene in neuroblastoma[J]. Oncogene, 2001, 20(32): 4424-4432.
  • 10Lawrence D, Shahrokh Z, Marsters S, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions [J]. Nat Med, 2001, 7(4): 383-385.

二级参考文献6

  • 1萨姆布鲁克 金冬雁(译).分子克隆实验指南,第2版[M].北京:科学出版社,1998.55-56.
  • 2Ashkenazi A,J Clin Invest,1999年,104卷,2期,155页
  • 3刘昌孝,药物评价实验设计与统计学基础,1999年,17页
  • 4金冬雁(译),分子克隆实验指南(第2版),1998年,55页
  • 5Snell V,Br J Haematol,1997年,99卷,3期,618页
  • 6Pan G,Science,1997年,277卷,5327期,815页

共引文献13

同被引文献51

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部